Teratogenic effects of warfarin images
Reading File
Searching Images
warfarin teratogenic effects fetal warfarin syndrome
Finding Sources
Loading Image
Loading Image
Finding Sources
Searching Images
warfarin embryopathy nasal hypoplasia stippled epiphyses X-ray
Loading Image
Loading Image
Loading Image
Reading File
Here is a comprehensive visual and clinical overview of the teratogenic effects of warfarin (Warfarin Embryopathy Syndrome):
Warfarin Embryopathy — Clinical Images
1. Fetal Facial Dysmorphism — Nasal Hypoplasia & Midface Flattening
Postmortem specimen (~18 weeks gestation). Classic warfarin embryopathy facial findings: markedly short nose, flat nasal bridge, perialar flattening, and overall midface hypoplasia — resulting from warfarin's inhibition of vitamin K-dependent carboxylation of matrix Gla protein (MGP), which is critical for nasal cartilage development.
2. Internal Organ Malformations — Pulmonary Hypoplasia & Diaphragmatic Hernia
Postmortem dissection (~21 weeks). Demonstrates bilateral pulmonary hypoplasia with rightward mediastinal shift and a left-sided diaphragmatic hernia — abdominal viscera herniated into the thoracic cavity, compressing lung development.
3. Radiograph — Stippled Epiphyses (Chondrodysplasia Punctata)
Neonatal upper limb X-ray. Punctate calcifications ("stippling") within cartilaginous epiphyses of the proximal humerus and elbow — the hallmark radiographic finding of warfarin-induced chondrodysplasia punctata. Warfarin inhibits vitamin K-dependent proteins required for normal epiphyseal calcification.
4. Radiograph — Skull, Cervical Spine & Tracheal Calcifications
Lateral X-ray. Shows platyspondyly (flattened vertebral bodies), irregular endplates, stippled epiphyses, midface hypoplasia with depressed nasal bridge, and tracheal cartilage calcifications — the full skeletal phenotype of chondrodysplasia punctata.
5. Radiograph — Foot: Stippled Tarsal Calcifications
Neonatal foot. Multiple punctate calcifications concentrated in the posterior tarsal region (calcaneus, talus) with extension to phalanges — classic epiphyseal stippling pattern.
Summary: Warfarin Embryopathy Syndrome
| Feature | Details |
|---|---|
| Critical exposure window | 6–12 weeks gestation (organogenesis) |
| Risk | ~5% with standard doses; lower if warfarin dose <5 mg/day |
| Mechanism | Inhibits vitamin K-dependent carboxylation of MGP and other Gla-proteins essential for bone/cartilage development |
| Facial | Nasal hypoplasia, flat nasal bridge, midface hypoplasia |
| Skeletal (X-ray) | Stippled epiphyses (chondrodysplasia punctata), platyspondyly, brachytelephalangy |
| Internal | Pulmonary hypoplasia, diaphragmatic defects |
| CNS | Optic atrophy, mental impairment, microcephaly |
| 2nd/3rd trimester risks | Fetal and intrauterine hemorrhage (CNS bleeds, placental bleeding) |
| Safe alternative | LMWH throughout pregnancy (preferred) |
Source: Creasy & Resnik's Maternal-Fetal Medicine, 9th ed.; Braunwald's Heart Disease
Search for recent clinical guidelines on anticoagulation in pregnancy
Reading File
Searching PubMed
"anticoagulation"[MeSH Terms] AND "pregnancy"[MeSH Terms]
Searching the Web
anticoagulation pregnancy clinical guidelines 2024 2025 ACOG ASH ESC
Searching PubMed
"heparin" AND "pregnancy" AND "thromboembolism"
Reading Web Page
anticoagulation pregnancy warfarin heparin LMWH recommendations
Reading Article
Reading Article
Reading Article
Here is a synthesis of the most recent clinical guidelines and high-quality evidence on anticoagulation in pregnancy:
Recent Guidelines: Anticoagulation in Pregnancy
🏛️ 2025 ESC Guidelines — Cardiovascular Disease in Pregnancy
(European Society of Cardiology, 2025 — most current major guideline)
The ESC 2025 guidelines include a dedicated anticoagulation chapter with these key recommendations:
Agent Selection
| Indication | Recommended Agent | Class |
|---|---|---|
| Acute VTE in pregnancy | Therapeutic weight-adjusted LMWH | I C |
| Mechanical heart valves (1st trimester) | LMWH or switch considerations | I C |
| Post-partum oral anticoagulation | Delay switch from heparin 7–14 days until wound healed | I C |
| DOACs (apixaban, rivaroxaban, dabigatran) | Contraindicated in pregnancy | III |
| Vitamin K antagonists (warfarin) | Safe during lactation; superior for mechanical valves (post-partum) | I |
Peridelivery Management
- High-risk women: convert LMWH → IV UFH ≥36 h before delivery; stop UFH 4–6 h before delivery; aPTT must normalize before regional anaesthesia. (I C)
- Low-risk women on therapeutic LMWH: neuraxial anaesthesia and vaginal delivery permitted 24 h after last LMWH dose. (I C)
- If delivery occurs while on VKAs or <2 weeks after stopping: caesarean section recommended for fetal protection. (I C)
- Planned delivery at ~39 weeks for women on antenatal anticoagulation, to avoid spontaneous labour while fully anticoagulated. (IIa C)
📊 Meta-Analysis — Anticoagulants in Pregnant Women with Prosthetic Heart Valves
[Systematic Review / Meta-Analysis · 2026] Shishesaz et al. J Cardiol [PMID: 40816699]
Key findings from 24 studies:
- Warfarin → lower valve thrombosis risk (1%) but higher fetal complications (embryopathy, abortion, preterm labour); risk is substantially reduced at <5 mg/day
- LMWH/UFH → better fetal outcomes but higher valve thrombosis rate (28%) vs warfarin
- Thromboembolic events: LMWH 3%, UFH/LMWH combined group higher than warfarin
- Conclusion: No single universally superior strategy — individualize based on maternal vs. fetal risk balance
📋 Practice Guideline — VTE Prevention in Inherited Thrombophilia
[Practice Guideline · 2026] Rath et al. Arch Gynecol Obstet [PMID: 41961304]
- Women with inherited thrombophilia represent >15% of pregnant population; thrombophilia raises VTE risk up to 40-fold
- High-risk thrombophilia (homozygous Factor V Leiden, homozygous prothrombin G20210A mutation, compound heterozygosity, antithrombin deficiency): heparin prophylaxis antepartum + 6 weeks postpartum regardless of family history
- Low-risk thrombophilia (heterozygous FVL, heterozygous prothrombin mutation): pharmacological prophylaxis only if positive family history or additional VTE risk factors
- No RCT evidence yet that pharmacological prophylaxis significantly reduces VTE in these women — decisions remain individualised
🔬 Systematic Review — DOACs in Pregnancy
[Systematic Review · 2022] Areia & Mota-Pinto. J Perinat Med [PMID: 35073471]
- 339 reported cases of DOAC use in pregnancy analyzed
- Live birth rate: 56%; miscarriage: 22.2%; fetal abnormalities related to DOACs: 3.6%
- Higher fetal loss and fetal abnormalities vs LMWH
- Conclusion: DOACs cannot be considered safe in pregnancy — consistent with all current guideline contraindications
Summary: Current Consensus
| Drug | 1st Trimester | 2nd/3rd Trimester | Post-partum |
|---|---|---|---|
| LMWH | ✅ Preferred (no fetopathy) | ✅ Preferred | ✅ Preferred until wound healed (7–14 days) |
| UFH | ✅ Acceptable | ✅ Acceptable | ✅ Acceptable |
| Warfarin | ⚠️ Avoid (embryopathy risk; use if <5 mg/day for mechanical valves) | ⚠️ Fetal hemorrhage risk | ✅ Safe; preferred for mechanical valves |
| DOACs | ❌ Contraindicated | ❌ Contraindicated | ✅ Safe (post-partum) |
Key principle across all 2025 guidelines: LMWH is the backbone of anticoagulation throughout pregnancy. The warfarin-vs-LMWH debate persists specifically in mechanical heart valve patients, where warfarin's superior thrombotic protection must be weighed against its teratogenicity (especially in the first trimester at doses >5 mg/day).
Interpret this into report paper
Reading File
Running Command
Running Command
Running Command
Writing File
Running Command
Running Command
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
Create a PDF summary of the radiology report
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.